Trillium Therapeutics (TRIL) Announces Presentation of Initial TTI-621 Data in AMMs
Tweet Send to a Friend
Trillium Therapeutics Inc. (Nasdaq: TRIL) presented data from an ongoing study with its lead drug candidate, TTI-621, in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
